---
document_datetime: 2025-07-02 12:27:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/stivarga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: stivarga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5126155
conversion_datetime: 2025-12-27 16:43:22.650402
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Stivarga

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | C.I HUMAN AND VETERINARY MEDICINAL | 01/07/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282349   | PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon. - Accepted                                                                                                                                                                                                                                                                                                                                        |            |     |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for | 27/03/2025 | N/A | EMA/VR/0000262120 |

<div style=\"page-break-after: always\"></div>

| place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |
|---------------------------------------------------------------------------------------------------------------|